title: [Efficacy of uro-vaxom in recurrent infectious-inflammatory diseases of the urogenital system].
abstract: Our study prospects of urovaxom in improvement of efficacy and prevention of recurrent urogenital infection. One capsule of oral vaccine uro-vaxom was given daily for a month to 127 patients: 23 males with chronic bacterial prostatitis/urethroprostatitis, 75 females with chronic cystitis, 29 females with urolithiasis complicated with secondary chronic pyelonephritis. Control examination was made each two months for a year. In signs of inflammation the patients received one more course of uro-vaxom for a month. It was followed by control examinations each three month for a year. We observed a 6-12 month "cold" period after one course of uro-vaxom in 86.7% patients. After the second course of immunoprophylaxis recurrent urogenital infection occurred 8 times less often. Thus, immunoprophylaxis of urogenital infection with oral vaccine uro-vaxom is highly effective, is well tolerated and, therefore, must enter the standards of medical care for patients with urogenital infection.
authors: E V
authors: EV
authors: Kul'chavenia
authors: A A
authors: AA
authors: Breusov
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000627:therapeutic use*; D000328:Adult; D004926:Escherichia coli / Q000276:immunology; D005260:Female; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D008297:Male; D008875:Middle Aged; D011472:Prostatitis / Q000175:diagnosis / Q000276:immunology / Q000517:prevention & control*; D055502:Secondary Prevention; D016896:Treatment Outcome; D014552:Urinary Tract Infections / Q000175:diagnosis / Q000276:immunology / Q000517:prevention & control*; D055815:Young Adult
chemical_list: D000276:Adjuvants, Immunologic